Abstract
Background: The initial mass vaccination's effectiveness has diminished, necessitating accelerated immunization coverage scaling. China has shifted nucleic acid testing from large-scale to voluntary. This study assesses the effectiveness and cost-effectiveness of different booster vaccination strategies in China. Methods: A dynamic transmission model divided the population into three groups: 0-19, 20-59, and 60+ years. We evaluated the effectiveness and cost-effectiveness of three vaccination strategies based on previous studies and public databases. Three scenarios were modeled and compared to no-continuation-vaccination to calculate averted diseases, deaths, and net benefits. One-way sensitivity analysis and probabilistic sensitivity analysis assessed findings' stability. Results: COVID-19 vaccination had significant health benefits compared to no continuing vaccination. Strategy II (prioritizing vaccinated 20-59-year-olds, then vaccinated 60+ individuals, and finally 0-19-year-olds) was the most cost-effective. Strategy I (prioritizing unvaccinated 60+ individuals, then 20-59, and finally 0-19) prevented the most deaths. Strategy II was the most cost-effective, with a total cost of 93,995,223,462 USD and the highest net benefit of 3,054,475,908,551,960 USD. Strategy II resulted in the highest number of avoided cases across categories, including infected, asymptomatic, mild/moderate, severe, and critical cases. Each strategy's effects on preventing new cases and critical illness were comparable. Sensitivity analyses confirmed the results' reliability. Conclusion: Prioritizing vaccinated 20-59-year-olds, then vaccinated 60+ individuals, and finally 0-19-year-olds was the most effective prevention strategy. The vaccination strategy should be tailored to the pandemic situation and available medical resources for maximum health gains.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have